



King's Research Portal

DOI:

[10.1016/j.bmcl.2019.02.011](https://doi.org/10.1016/j.bmcl.2019.02.011)

Document Version

Peer reviewed version

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Goncalves, M. B., Clarke, E., Jarvis, C., Kalindjian, S. B., Pitcher, T., Grist, J., Hobbs, C., Carlstedt, T., Jack, J., Brown, J. T., Mills, M., Mumford, P., Borthwick, A. D., & Corcoran, J. P. T. (2019). Discovery and lead optimisation of a potent, selective and orally bioavailable RAR agonist for the potential treatment of nerve injury. *Bioorganic & medicinal chemistry letters*, 29(8), 995-1000. <https://doi.org/10.1016/j.bmcl.2019.02.011>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Accepted Manuscript

Discovery and lead optimisation of a potent, selective and orally bioavailable RAR β agonist for the potential treatment of nerve injury

Maria B. Goncalves, Earl Clarke, Christopher Jarvis, S. Barret Kalindjian, Thomas Pitcher, John Grist, Carl Hobbs, Thomas Carlstedt, Julian Jack, Jane T. Brown, Mark Mills, Peter Mumford, Alan D. Borthwick, Jonathan P.T. Corcoran


PII: S0960-894X(19)30087-3
DOI: <https://doi.org/10.1016/j.bmcl.2019.02.011>
Reference: BMCL 26291

To appear in: *Bioorganic & Medicinal Chemistry Letters*

Received Date: 3 January 2019
Revised Date: 6 February 2019
Accepted Date: 10 February 2019

Please cite this article as: Goncalves, M.B., Clarke, E., Jarvis, C., Kalindjian, S.B., Pitcher, T., Grist, J., Hobbs, C., Carlstedt, T., Jack, J., Brown, J.T., Mills, M., Mumford, P., Borthwick, A.D., Corcoran, J.P.T., Discovery and lead optimisation of a potent, selective and orally bioavailable RAR β agonist for the potential treatment of nerve injury, *Bioorganic & Medicinal Chemistry Letters* (2019), doi: <https://doi.org/10.1016/j.bmcl.2019.02.011>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Discovery and lead optimisation of a potent, selective and orally bioavailable RAR β agonist for the potential treatment of nerve injury.

Maria B. Goncalves,^a Earl Clarke,^a Christopher Jarvis,^a S. Barret Kalindjian,^a Thomas Pitcher^a, John Grist^a, Carl Hobbs^a, Thomas Carlstedt^a, Julian Jack^a, Jane T. Brown,^b Mark Mills,^b Peter Mumford,^b Alan D. Borthwick,^{c*} and Jonathan P. T. Corcoran^{a*}

^aNeuroscience Drug Discovery Unit, Wolfson Centre for Age-Related Diseases, Guy's Campus, King's College, London SE1 1UL, UK.


^cDrugMolDesign, 15 Temple Grove, London NW11 7UA, UK.

^bSygnature Discovery Limited, Biocity, Pennyfoot Street, Nottingham NG1 1GF, UK.

Abstract.

Oxadiazole replacement of an amide linkage in an RAR α agonist template **1**, followed by lead optimisation, has produced a highly potent and selective RAR β agonist 4-(5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl)benzoic acid (**10**) with good oral bioavailability in the rat and dog. This molecule increases neurite outgrowth *in vitro* and induces sensory axon regrowth *in vivo* in a rodent model of avulsion and crush injury, and thus has the potential for the treatment of nerve injury.

Graphical Abstract



Key words


Retinoic acid receptor, beta agonist, SAR, Neurite outgrowth, Axon regrowth, C286.

There are no effective treatments for nerve injuries including spinal cord injuries (SCI), stroke, and peripheral nerve injuries. However it has been shown¹ that stimulating the retinoid signalling pathway in animal models of nerve injury leads to axonal outgrowth and functional recovery. This pathway is activated by retinoic acid (RA) binding to retinoic acid receptors (RAR) that acts in the nucleus to drive the synthesis of RNA and hence produce proteins for axonal outgrowth. Corcoran *et al.*,² have shown that RAR β signalling is required for retinoid mediated neurite outgrowth of neurons. In contrast, signalling by RAR α , RAR γ or the RXRs has no effect on this action. It has been shown³ that the RAR β agonist, CD2019, can activate the RAR β receptor in a dose dependent manner. This initiates axonal outgrowth in models of nerve injury and leads to functional recovery. However CD 2019 is a highly lipophilic compound that is not

significantly orally bioavailable and shows only weak to moderate selectivity over RAR α and RAR γ receptors. AG 261066, more recently described as a selective RAR β agonist is less potent than CD 2019 and less selective than the latter over RAR α (Table 4). Our aim was to identify a more drug-like, highly potent and selective RAR β agonist that was orally bioavailable and which had the potential to be useful in the treatment of nerve injury.

Recently, we discovered a novel and selective RAR α agonist 4-[(3,5-dichloro-4-ethoxybenzoyl)amino]benzoic acid **1**. This template was the basis of a lead optimisation exercise which led to an orally bioavailable and highly potent RAR α agonist with high selectivity against RAR β and RAR γ .⁴ As part of this exercise, it was decided to modify the amide linkage between the two rings by replacing it with a variety of 5-membered heterocycles (Table 1). Changing the amide linkage in **1** to thiazole and imidazole gave derivatives **2** and **3** that were weakly active as RAR α agonists, but were more potent than amide **1** as RAR β agonists, although only weakly selective for RAR β vs RAR α . The oxazole **4** was >40-fold more potent than **1** as an RAR β agonist and had similar agonist potency for all three subtypes.

Table 1. Heterocyclic derivatives in RAR α , β and γ transactivation assays.^a



compd	Het	α EC ₅₀ nM ^a	β EC ₅₀ nM ^a	Fold Selectivity for β over α ^b	γ EC ₅₀ nM ^a	Fold Selectivity for β over γ ^b	cLogP ^d
ATRA	-	1.9	1.2	1.56	0.9	0.75	
1	-	46	1227	0.037	30000	24	4.4
2		240 ^c	120	2	160	1.3	6.1
3		594 ^c	423	1.4	ND	-	5.6
4		60	28	2.1	45	1.6	5.5
5		18 ^c	1.5	12	28	19	5.1
6		31	110	0.28	5.4	0.05	5.1
7		58	63	0.92	150	2.4	4.3

^a Transactivation assays for the RAR alpha, beta and gamma receptors were performed using each of the mouse RAR ligand binding domains. Values usually obtained from three separate experiments. Errors in these assays are approximately 20% of the mean values. Transactivation Assays details see Supplementary data and reference 4. ATRA is all trans retinoic acid.


^b The EC₅₀ ratios of α to β and γ to β .








^c Compound behaves as a partial agonist relative to the amplitude of the normalising ATRA output. All other compounds were determined to be full agonists with their maximum upper asymptote within 20% of that found for ATRA.

^d reference 9.

Surprisingly however, increasing the number of heteroatoms in the heterocyclic ring to give the oxadiazole **5** resulted in a highly potent RAR β agonist and that had 12- and 19-fold selectivity as an agonist over RAR α and RAR γ respectively. This RAR β agonist selectivity and potency was lost when the isomeric 1,2,4-oxadiazol-5-yl benzoic acid derivative **6** and the 1,3,4-oxadiazol-2-yl benzoic acid compound **7** were examined.

Table 2 1,2,4-oxadiazol-3-yl benzoic acid derivatives in RAR α , β and γ transactivation assays^a



compd	X	β EC ₅₀ nM ^a	α EC ₅₀ nM ^a	Fold Selectivity for β over α ^b	γ EC ₅₀ nM ^a	Fold Selectivity for β over γ ^b	cLogP ^d
ATRA	-	1.9	1.2	0.9	0.6	0.5	
5		1.5	18 ^c	28	12	19	5.1
8		4200	18	17	0.0043	0.0041	7.2
9		1.4	4	3	2.8	2.1	7.2
10		1.9	26	11	13	5.6	5.3
11		2.5	19	5.3	7.6	2	5.3
12		3.4	30	6.3	9	2	5.8
13		11	114	83	10	7.5	4.1

^{a, b, c, d} See Table 1


To try and exploit the selective and potent RAR β agonist activity of the 1,2,4-oxadiazol-3-yl benzoic acid derivative **5**, a series of replacements for the 3,5-dichloro-4-ethoxyphenyl ring with other heterocyclic and aryl rings found in known RAR agonists were investigated (Table 2). The 5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene ring used in AM580,⁵ the 3,5 di-^t-butylphenyl ring in Am555,⁵ the 4,7-dimethylbenzofuran ring in ER38925⁶ and the 4-trifluoromethyl-7-fluorobenzofuran ring found in E6060,⁷ were investigated.

Relative to **5**, derivative **8** lost >2700-fold in potency as a RAR β agonist whilst retaining most of its potency at RAR α . Compound **9** which retained good RAR β agonist potency, lost all RAR β selectivity and was essentially a potent pan-RAR agonist having a similar potency at all three subtypes. In contrast, the 4,7-dimethylbenzofuran derivative **10** maintained a similar potency and selectivity profile to **5** and as we were keen to move away from the dichlorophenyl motif found in a number of herbicides, this now became our lead compound.

Compared to our lead **10**, the 4-trifluoromethyl-7-fluorobenzofuran **11** and the benzothiophene **12** analogues, are less RAR β / RAR α selective while the benzoxazole derivative **13** is less potent as a RAR β agonist (Table 2).

In an attempt to increase further the selectivity and agonist potency of compound **10**, a series of substitutions in the benzoic acid portion of the template were investigated (Table 3). The 2-fluoro compound **14** had a similar level of potency to **10** but lost some RAR β selectivity (Table 3) when compared to **10**. The 2-methyl **15**, 3-fluoro **16** and 3-methyl **17** derivatives all lost considerable potency as RAR β agonists when compared to **10**.

Table 3 Derivatives of 4-(5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl)benzoic acid in the RAR α , β and γ transactivation assays ^a




compd	R	β EC ₅₀ nM ^a	α EC ₅₀ nM ^a	Fold Selectivity for β over α ^b	γ EC ₅₀ nM ^a	Fold Selectivity for β over γ ^b	cLogP ^d
10	H	1.9	26	11	13	5.6	5.3
14	2-F	2.2	16	8.4	7.3	3.8	5.1
15	2-Me	14	89	25	6.4	1.8	5.5
16	3-F	11	61	3.7	5.5	0.33	5.5
17	3-Me	47	600	14	13	0.3	5.5

^{a, b, d} See Table 1

With this information and other data not shown, it became apparent that substitution in the benzoic acid ring in this series did not increase potency at RAR β , which is in contrast to observations made in the analogous RAR α agonist series.⁴

The lead RAR β agonist **10** has a high potency at RAR β (similar potency to ATRA) and behaves as a full agonist. It has a selectivity for RAR β over RAR α of 13-fold, while selectivity for RAR β over RAR γ is 5.6-fold.

Table 4 Selective RAR β agonists



compd	β EC ₅₀ nM ^a	α EC ₅₀ nM ^a	γ EC ₅₀ nM ^a	Fold Selectivity for β over α ^b	Fold Selectivity for β over γ ^b	cLogP ^d
10	1.9	26	11	13	5.6	5.3
AC 261066	12	70	33	5.8	2.8	4.9
CD 2019	0.83	9.2	1.6	11	1.9	8.0

^{a, b, d} See Table 1.

Comparison of **10** with the selective RAR β agonist AC-261066⁸ showed that in our hands, **10** is a more potent and selective RAR β agonist (Table 4). Whilst compound **10** is marginally less potent than CD 2019, it has a better selectivity for RAR β over RAR α and RAR γ and is over two orders of magnitude less lipophilic. The more drug-like template present in **10** translates into a good *in vitro* and *in vivo* profile for this RAR β agonist (Table 5). In comparison to the mouse transactivation data shown in Table 4, we also confirmed that **10** had a similar RAR β potency (EC₅₀ = 2.05 nM), similar fold selectivity for RAR β over RAR α (23 fold) and for RAR β over RAR γ (5 fold) against the human RAR ligand-binding domains,⁴ before further predevelopment studies were investigated.

Table 5 Physico-chemical and *in vitro* properties of RAR β agonist **10**

LogD ^a	Solubility ^b	MDCK ^c	MDCK ^c	Cyp450 ^d	Human Cl _{int} ^e
7.4	μ M pH 7.4	Papp $\times 10^{-6}$ cm/s	asymmetry ratio	IC ₅₀ μ M	μ L/min/mg protein
2.8	>100	28	0.8	>25	<1

^a Measured by shake flask method.

^b as the amorphous sodium salt.

^c MDR1-MDCK cell line.

^d Cyp450 inhibition profile for isoforms 1A2, 2C9, 2C19, 2D6, 3A4.

^e Human microsomes incubated with the test compound at 37°C in the presence of the co-factor, NADPH. The data is the mean on 5 separate experiments. Compound disappearance monitored over 45 min period. SEM is less than 10% of the mean values.

For ^{a, b, c, d, e} see reference 9

The potential drug candidate **10** has excellent physico-chemical properties. It is sufficiently water soluble ($>100 \mu\text{M}$ as the sodium salt) and showed good permeability. The efflux ratios obtained from bi-directional permeability tests was close to unity indicating that **10** is likely not a PGP substrate. With no significant inhibition $\text{IC}_{50} > 25 \mu\text{M}$ against five Cyp450 isozymes (1A2, 2C9, 2C19, 2D6, 3A4), a human and mouse plasma protein binding of 98% and 95% respectively and showing very high stability in human microsomes, this compound was progressed to pharmacokinetic studies.

Table 6. Pharmacokinetic data for Compound **10** in Rat and Dog.¹²

Species	Clearance mL/h/kg	Volume Distribution ss mL/kg	$t_{1/2}$ h	T_{max} h	Fraction absorbed %
rat ^a	3.7	0.41	1.4	1.7	80 ^b
dog ^c	1.1	0.23	2.5	1.0	45

^a iv dose 0.5 mg/kg administered in 4% DMSO, 38% PEG-400, 58% (0.9%) NaCl. Oral doses of 1, 3 and 10 mg/kg prepared in 8% ethanol and 92% PEG-400.


^b Based on mean of data obtained at 1, 3 and 10 mg/kg oral dose levels in comparison to iv dose of 0.5 mg/kg.

^c iv dose 0.5 mg/kg administered in 2% DMSO, 98% aqueous hydroxypropyl- β -cyclodextrin (22.5% w/v). Oral dose 3 mg/kg administered in 3% DMSO, 97% aqueous hydroxypropyl- β -cyclodextrin (22.5% w/v). For assay description ^{a, c} see reference 4.

As shown in Table 6 compound **10** was found to possess a promising pharmacokinetic profile in both rat and dog. It demonstrated a low rate of blood clearance, a moderate half-life and good oral bioavailability. It was also found to penetrate the CNS, with nearly equivalent amounts detected in brain tissue when compared to plasma, 8h after dosing orally to rats.

In the HEPG2 cell toxicity assay **10** was found to be completely devoid of alerts at the highest concentration tested ($50 \mu\text{M}$). Furthermore, in a binding assay for HERG channels, the compound, demonstrated no inhibition at $10 \mu\text{M}$. Genetic toxicity testing of the material showed that it was inactive in bacterial cytotoxicity tests up to $100 \mu\text{M}$ and in an Ames test in three bacterial strains. Similar, negative results were obtained in an *in vitro* micronucleus test in CHO-K1 cells, in both the presence and absence of S9.


Synthesis and characterisation of compounds in Table 1-3 have been described¹⁰ and involve standard preparation of the 5-membered heterocyclic rings. This is illustrated by the preparation of our lead oxadiazole **10** outlined in Scheme 1.

Scheme 1 Synthesis of oxadiazole **10**.

Reagents and conditions: (a) T3P, EtOAc, DMF, Et₃N, 0 °C, then warmed to 90°C and stirred for 18 h; (b) LiOH (2 M, aq.), THF, 40°C for 20 h. then at RT HCl (1 M) added (see Supplementary data for full experimental and spectroscopic details).

Compound **10** was evaluated for neurite outgrowth/branching in cerebellar cultures. Cerebellar cultures grown on a monolayer of CHO-MAG were treated with RAR β agonists and neurite outgrowth was assessed by immunostaining and neurite length quantification.¹⁰ The compound increased neurite length in a dose dependant manner (Figure 1) and thus has the potential to be useful in the treatment of nerve injury.

Figure 1 Effects of RAR β agonists **10** on neurite outgrowth^a {image single,column}




^a Cerebellar neurons grown on a monolayer of CHO-MAG cells were treated for 24hr with either vehicle (V) or increasing doses of RAR β agonists (1×10^{-8} - 1×10^{-6} M). Both RAR β agonists increase neurite outgrowth in a dose dependant manner. Results are means from 3 independent experiments. Statistical analysis was done using Student's t-test between vehicle and each drug's highest dose. Error bars are SEM and ** $p < 0.001$, * $p < 0.01$.

The novel RAR β agonist **10** has also been demonstrated to be capable of inducing sensory axon regrowth *in vivo* in a rodent model of avulsion as shown in Figure 2, where avulsion is defined as the traumatic tear of nerve roots from the spinal cord causing injury. Rats were trained for two weeks prior to surgery in behavioural tasks and scores were recorded the day before surgery, the day after surgery and then weekly, for four weeks. Surgery was performed as previously described.^{11,12} In a sticky tape task, the time taken to sense and remove the tape from the paw of the lesioned forelimbs was measured. From

week three of treatment, significantly lower latencies were observed with the injured forelimbs of compound **10** treated rats (3mg/kg, po) compared to vehicle treated ones. In locomotor tasks, the number of foot slips in a horizontal ladder made by the injured forelimb of the compound **10** treated rats was also measured. This parameter was found to be markedly lower than that of vehicle treated rats from week two. Further details and data on an in vivo model of crush injury will be presented in due course.

Figure 2 Effects of oral administration of compound **10** in sensory and locomotor functions in avulsed rats^a



^a Dose 3mg/kg, po, three times a week, every other day. Data represent mean \pm SEM of $n=8$, ** $p \leq 0.005$, *** $p \leq 0.001$. Two-way repeated-measures ANOVA, Tukey's post-hoc test.

In summary, replacing the amide linkage between the two aromatic rings in our selective RAR α agonist template with 5-membered heterocycles, gave compounds which were selective as RAR β agonists. SAR exploration of the oxadiazole based series led to potent and selective RAR β agonists. In particular compound **10**, which will henceforth be referred to as **C286**, possesses favourable physicochemical properties with an oral bioavailability of >40% in both rats and dogs, a good overall PK profile and drug-

like properties. Furthermore, it has been shown to be inactive in cytotoxicity and genotoxicity screens. It has also been demonstrated here to increase neurite outgrowth *in vitro* and induce sensory axon regrowth *in vivo* in a rodent model of avulsion and crush injury and thus warrants further consideration as a potential therapeutic agent for the treatment of nerve injury.

Acknowledgements

We thank the MRC (Grant ref. no MR/R006466/1) and the Wellcome Trust (Grant ref. no 084286) for their financial support.


A. Supplementary data

Supplementary data including experimental, spectroscopic details and full analytical data for compound **10**, and transactivation assays for RAR alpha, beta and gamma receptors associated with this article can be found, in the online version, at <https://doi.org/xxxxx .bmcl.2019.yyyy>

References

1. Maden M. Retinoids in neural development. In: Nau H, Blaner WS, eds. *Handbook of experimental pharmacology*. Heidelberg: Springer-Verlag; 1999:399-442.
2. Corcoran J, Shroot B, Pizzey J, Maden M. The role of retinoic acid receptors in neurite outgrowth from different populations of embryonic mouse dorsal root ganglia. *J Cell Sci*. 2000;113:567-2574.
3. Agudo M, Yip P, Davies M, Bradbury E, Doherty P, McMahon S, Maden M, Corcoran JP. A retinoic acid receptor β agonist (CD2019) overcomes inhibition of axonal outgrowth via phosphoinositide 3-kinase signalling in the injured adult spinal cord. *Neurobiol Dis*. 2010; 37:147-155.
4. Clarke E, Jarvis CI, Goncalves MB, Kalindjian SB, Adams DR, Brown JT, Shiers JJ, Taddei DMA, Ravier E, Barlow S, Miller I, Smith V, Borthwick AD, Corcoran JPT. Design and synthesis of a potent, highly selective, orally bioavailable, retinoic acid receptor alpha agonist. *Bioorg Med Chem*. 2018;26:798-814.
5. Kagechika H, Kawachi E, Hashimoto Y, Shudo K, Himi T. Retinobenzoic acids. 1. Structure-activity relationships of aromatic amides with retinoid activity. *J Med Chem*. 1988;31:2182-2192.
6. Seino KI, Yamauchi T, Shikata K, Kobayashi S, Nagai M, Taniguchi M, Fukao K. Prevention of acute and chronic allograft rejection by a novel retinoic acid receptor- α - selective agonist. *Int Immunol*. 2004;16:665-673.
7. Yamauchi T, Ishibashi A, Shikata K, Tokuhara N, Seino KI, Kobayashi S, Nagai M. Effect of E6060 [4-{5-[7-fluoro-4-(trifluoromethyl) benzo [b] furan-2-yl]-1H-2-pyrrolyl} benzoic acid], a novel subtype-selective retinoid, on lupus-like nephritis in female (NZBxNZW) F1 mice. *J Pharmacol Exp Ther*. 2005;312:938-944.
8. Lund BW, Knapp AE, Piu F, Gauthier NK, Begtrup M, Hacksell U, Olsson R. Design, Synthesis, and Structure-Activity Analysis of Isoform-Selective Retinoic Acid Receptor β Ligands. *J Med Chem*. 2009;52:1540–1545.
9. For ADME assays and Biological assays including bacterial cytotoxicity and genetic toxicity assays, see reference 4.
10. Borthwick AD, Mills MT, Brown JT, Corcoran JPT, Goncalves MB, Kalindjian SB, 2016, PCT Patent Appl. WO 2016097004A1.
11. Goncalves MB, Malmqvist T, Clarke E, Hubens CJ, Grist J, Hobbs C, Trigo D, Risling M, Angeria M, Damberg P, et al. Neuronal RARbeta Signaling Modulates PTEN Activity Directly in Neurons and via Exosome Transfer in Astrocytes to Prevent Glial Scar Formation and Induce Spinal Cord Regeneration. *J Neurosci*. 2015;35:15731-15745.
12. All animal studies were ethically reviewed and carried out in accordance with the United Kingdom Animals (Scientific Procedures) Act 1986 by the local veterinarian for the rat model of avulsion (see Ref. 11), and by CXR Biosciences Ltd, James Lindsay Place, Dundee Technopole, Dundee DD 5JJ, for the rat and dog PK (see Ref. 4)

Graphical Abstract



ACCEPTED MANUSCRIPT